Trials / Completed
CompletedNCT06030232
Transarterial Radioembolization (TARE) in COlorectal MEtastasis of Liver
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 202 (actual)
- Sponsor
- Ankara University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Radioembolization is an established treatment option for patients with unresectable primary and secondary liver tumors. Microspheres containing 90Y are injected intraarterially to deliver a high radiation dose to the tumors. Despite of our knowledge on the effectiveness of 90Y glass microspheres in the treatment of HCC, literature data on the treatment of metastatic colorectal cancer (mCRC) patients with 90Y glass microspheres is limited. In the recent EANM guideline variable healthy liver doses are recommended for patients with mCRC with an effective tumor dose recommendation based on a study with limited number of patients. Primary objectives; Investigate effective tumor dose and safe healthy liver dose in radioembolization for colorectal cancer liver metastasis using multicompartment dosimetry Secondary objectives; Investigate dose-response and dose-toxicity relationships, time to progress, concordance between pretreatment and posttreatment dose calculations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Therasphere | Transarterial radioembolization |
Timeline
- Start date
- 2024-01-15
- Primary completion
- 2024-03-15
- Completion
- 2024-04-15
- First posted
- 2023-09-08
- Last updated
- 2024-04-24
Locations
8 sites across 1 country: Turkey (Türkiye)
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT06030232. Inclusion in this directory is not an endorsement.